	1	DARRYL M. WOO (CSB No. 100513) CHARLENE M. MORROW (CSB No. 1364	11)	
FENWICK & WEST LLP ATTORNEYS AT LAW MOUNTAIN VIEW	2	RYAN J. MARTON (CSB No. 223979) C. J. ALICE CHUANG (CSB No. 228556) DENNIS FAIGAL (CSB No. 252829) FENWICK & WEST LLP 555 California Street, 12th Floor San Francisco, CA 94104		
	3			
	4			
	5	Telephone: (415) 875-2300 Facsimile: (415) 281-1350		
	6	Attorneys for Defendants		
	7	AMBU A/S, AMBU INC., AMBU LTD., and AMBU SDN. BHD.		
	8	UNITED STATES DISTRICT COURT		
	9	SOUTHERN DISTRICT OF CALIFORNIA		
	10			
	11	THE LADVAIGE AL MACK COMPANY		07 01000 DMG M G
	12	THE LARYNGEAL MASK COMPANY LTD. and LMA NORTH AMERICA,		:07-cv-01988-DMS-NLS
	13	INC.,		ANTS AMBU A/S, AMBU INC., 'D., AND AMBU SDN. BHD.'S
	14	Plaintiffs,	OPPOSITI MOTION	ION TO PLAINTIFFS' <i>EX PARTE</i> TO MODIFY THE PROTECTIVE
	15	V.	ORDER	
	16	AMBU A/S, AMBU INC., AMBU LTD., and AMBU SDN. BHD.,	Judge:	Honorable Nita L. Stormes
	17	Defendants.		
	18			
	19	AMBU A/S, AMBU INC., AMBU LTD., and AMBU SDN. BHD.,		
	20	Counterclaimants,		
	21	v.		
	22	THE LARYNGEAL MASK COMPANY LTD. and LMA NORTH AMERICA, INC.,		
	23			
	24	Counter-Defendants.		
	25			
	26			
	27			
	28			

CASE No. 3:07-CV-01988-DMS-NLS

AMBU'S OPP. TO PLFS.' *EX PARTE* MOTION TO MODIFY THE PROTECT. ORDER

Defendants Ambu A/S, Ambu Inc., Ambu Ltd. and Ambu Sdn. Bhd (collectively "Ambu") hereby oppose plaintiffs The Laryngeal Mask Company Ltd.'s and LMA North America, Inc.'s (collectively "LMA") *Ex Parte* Motion to Modify the Protective Order. LMA's request that the Court modify the Protective Order already entered in this case (Dkt. No. 74) to allow Mr. Stephen Marzen full access to Ambu's competitively sensitive business information produced in this case should be denied. The fervor with which LMA has pursued this issue evidences how important the Court's ruling is to protecting Ambu's confidential information. LMA's request is based entirely on the formality of Mr. Marzen's recent resignation from the Board of Directors for two companies (Venner Capital S.A. ("Venner") and LMA International N.V. ("LMA International")) that are part of the LMA's corporate family as well as his resignation from LMA International's Intellectual Property Committee. Such resignations, though, have not effected a substantive change to Mr. Marzen's ongoing role at LMA and should not change this Court's decision regarding Mr. Marzen's access to Ambu confidential information.

# I. MR. MARZEN SHOULD NOT BE GIVEN ACCESS TO AMBU'S SENSITIVE BUSINESS INFORMATION

On August 21, 2008 this Court ruled that given Mr. Marzen's role as a member of the Venner and LMA International Board of Directors and role as the Chair of the LMA International Intellectual Property Committee, he should not be allowed access to Ambu confidential information. Transcript of August 21, 2008, Discovery Hearing at 7:6-10. That ruling was based in large part on Mr. Marzen's involvement in advising LMA on intellectual property enforcement issues. In particular, the Court was concerned with the fact that such intellectual property enforcement necessarily involves analyzing the competition in order to determine whether to sue competitors who may infringe LMA Group's patents. The Court concluded that "Mr. Marzen's advice and counsel to LMA to the Intellectual Property Committee necessarily affects licensing decisions and he is, therefore, a competitive decision maker for LMA." *Id.* at 7:18-21.

Although Mr. Marzen has resigned from the LMA International and Venner Boards and the Intellectual Property Committee, LMA lawyers have confirmed that Mr. Marzen will continue

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

advising LMA on intellectual property enforcement issues. See Declaration of Ryan Marton in Support of Defendants Ambu A/S, Ambu Inc., Ambu Ltd., and Ambu Sdn. Bhd.'s Opposition to Plaintiffs' Ex Parte Motion to Modify the Protective Order ("Marton Decl.") ¶ 6. On September 2, 2008, in response to LMA's request for a stipulation allowing Mr. Marzen's access to confidential Ambu information in light of Mr. Marzen's resignations, Ambu requested further information regarding Mr. Marzen's ongoing relationship with LMA including whether he would continue attending board meetings, whether he would continue to consult with LMA on intellectual property and business issues, and whether Mr. Marzen would confirm in writing that he would refrain from consulting with LMA on IP and business issues for some time period after the resolution of this current lawsuit. Marton Decl. ¶¶ 2, 3, Exh. A. LMA did not formally respond to this request but its lawyer did confirm that going forward Mr. Marzen would continue to advise LMA on intellectual property enforcement issues and attend LMA Board meetings where such issues are discussed. Marton Decl. ¶ 6. Indeed, in his supplemental declaration filed with the current motion, Mr. Marzen merely confirms that he is no longer on any LMA affiliated boards and no longer on the LMA Intellectual Property Committee. He indicates no other changes to his ongoing role with LMA. This is exactly the same type of advice and relationship that existed when the Court denied Mr. Marzen access to sensitive Ambu information, and raises the same risks of inadvertent disclosure of confidential business information. Simply put, the formality of resigning from LMA Board positions does not make it any more likely Mr. Marzen can scrub his brain of confidential information prior to advising LMA. LMA's current motion amounts to a request that the Court reconsider its order of August

21, 2008 barring Mr. Marzen from accessing Ambu's highly confidential information (Dkt. No. 70). As such, LMA has the burden to show "what new or different facts and circumstances are claimed to exist which did not exist, or were not shown" prior to the Court's entry of the original order. CivLR 7.1(i)(1). LMA has not met this burden because it has not shown facts that have sufficiently changed since the Court's entry of its order. Although LMA has identified Mr. Marzen's resignations from the LMA International and Venner Boards and the Intellectual Property Committee, LMA simply has not shown that Mr. Marzen's role and responsibilities with

2

3

4

5

6

7

8

9

10

11

1213

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

\_\_\_\_

LMA have meaningfully changed.

LMA's current motion asserts in a conclusory fashion that Mr. Marzen has never been involved with competitive licensing decisions. However, that is not supported by the record to date, which shows that Mr. Marzen has duties for LMA akin to those of in-house counsel. He has been responsible for "developing LMA's intellectual-property policies, supervising patent infringement litigation, and appointing outside counsel." See Marton Decl. at ¶ 4; Declaration of Stephen Marzen in Support of Plaintiff's Motion to Disqualify Finnegan Henderson Farabow Garrett & Dunner, LLP, ¶ 3 (Dkt. No. 17). He has also described that his role "includes identifying and suing those companies who infringe LMA Group patents." Marton Decl. ¶ 5, Exh. C. As such, he is involved in competitive decision making including who to sue on, and whether to license, the LMA patent portfolio. There is no evidence to suggest that Mr. Marzen's role with regard to this work has changed as a result of the formality that he has resigned some Board positions; in fact, counsel for LMA has confirmed that Mr. Marzen will continue to attend LMA Board meetings where LMA's intellectual property enforcement is to be discussed. Marton Decl. ¶ 6. This set of facts is remarkably similar to those on which the Court originally based its decision on this issue, and Ambu respectfully requests that the current protective order remain in place. See Intel Corp. v. VIA Techs., Inc., 198 F.R.D. 525, 529-531 (N.D. Cal. 2000) (holding that in-house counsel's "involvement in licensing through litigation constitutes competitive decisionmaking . . . ").

In addition, a review of the record shows that LMA's repeated assertions that Mr. Marzen is not involved in competitive decision-making is based on its artificial definitions of competitive decision-making as occurring only when products are designed or priced. *See e.g.*, Marton Decl. ¶ 5, Exh. C, ¶ 5. There is simply no basis in the applicable caselaw for such a narrow definition of competitive decision-making, nor is there any meaningful distinction between the risk of misuse of confidential information in the pricing context versus the risk of misuse in making competitive decisions about intellectual property or about corporate investments. In addition, there has been no showing that Mr. Marzen will cease to be involved in the venture capital investments of Venner, who as Mr. Marzen notes is involved in investing "in the shares of

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

companies that make or sell medical devices." *Id*. Certainly even LMA cannot contend that making decisions about venture investment is not competitive decision-making.

Ambu believes that there were, and continue to be, substantial concerns about the risk of Mr. Marzen's inadvertent disclosure of Ambu's highly confidential information to LMA for reasons beyond his mere title as director of LMA International and Venner. Given Mr. Marzen's continuing role with LMA, Ambu would suffer a significant competitive disadvantage if its highly confidential information were disclosed to LMA. For example, LMA's discovery requests call for the production of, *inter alia*, documents that include information on Ambu's pricing, profitability, customer satisfaction, product plans, and marketing and business strategies. See Marton Decl. ¶ 7, Exh. D. Such information is competively sensitive, and Ambu would not otherwise allow competitors to see it.

Ambu further maintains that the risk of disclosure outweighs the little prejudice that LMA will suffer. As this Court recognized in the August 21, 2008 hearing, the fact that LMA continues to be ably represented by trial counsel at Knobbe Martens Olson & Bear LLP and Shearman & Sterling LLP shows that limiting Mr. Marzen's access to Ambu information would not result in prejudice to LMA. See Transcript of August 21, 2008, Discovery Hearing at 8:16-21. Thus, Ambu respectfully requests that the Court deny LMA's motion to modify the Protective Order.

### II. MR. MARZEN SHOULD NOT BE GIVEN ACCESS TO AMBU'S SENSITIVE BUSINESS INFORMATION WITHOUT FIRST PERMITTING FULL EXPLORATION OF MR. MARZEN'S ROLES

Should the Court be inclined to grant LMA's current motion, Ambu respectfully requests it be first permitted to take the deposition of Mr. Marzen, and then to make a supplemental submission, regarding his ongoing role at LMA in order for Ambu and the Court to fully evaluate the propriety of Mr. Marzen's access to Ambu's confidential information.

24

25 ///

/// 26

/// 27

/// 28

# III. **CONCLUSION** For the foregoing reasons, Ambu respectfully requests the Court to deny LMA's Ex Parte Motion to Modify the Protective Order or, alternatively, to permit the deposition of Mr. Marzen regarding his ongoing role at LMA prior to entering a ruling on this motion. Dated: October 3, 2008 FENWICK & WEST LLP /s/ Dennis Faigal By: Attorneys for Defendants AMBU A/S, AMBU INC., AMBU LTD., and AMBU SDN. BHD. Email: dfaigal@fenwick.com

## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that all counsel of record who are deemed to have consented to electronic service are being served with a copy of this document via the Court's CM/ECF system per Local Rule 5.2 on October 3, 2008.

By: /s/ Dennis Faigal

Dennis Faigal

E-mail: dfaigal@fenwick.com